X4 Pharmaceuticals
Yahoo Finance • 2 months ago
X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference
BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team will participate in the upcoming Guggenh... Full story
Yahoo Finance • 2 months ago
Healthcare Rally: Pulmonx, UHS, And X4 Lead After-Hours Gains Amid Strategic Updates
(RTTNews) - Several healthcare and biotech stocks posted notable gains in after-hours trading on Monday, driven by earnings updates, executive appointments, and capital market activity. Pulmonx Corp. (LUNG) surged 33.33% to $2.08 as of 9:... Full story
Yahoo Finance • 2 months ago
X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million
BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced the closing of its previously announced u... Full story
Yahoo Finance • 2 months ago
X4 Pharmaceuticals drops 5%, prices $135M equity
* X4 Pharmaceuticals (NASDAQ:XFOR [https://seekingalpha.com/symbol/XFOR]) priced [https://seekingalpha.com/pr/20278619-x4-pharmaceuticals-announces-pricing-of-135-million-underwritten-public-offering] its previously announced underwritte... Full story
Yahoo Finance • 2 months ago
X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering
BOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced the pricing of its previously announced u... Full story
Yahoo Finance • 3 months ago
Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide
Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises GAITHERSBURG, Md., Sept. 29,... Full story
- ALT
Mentioned:
Yahoo Finance • 3 months ago
X4 Pharmaceuticals to reduce 50% of workforce
* X4 Pharmaceuticals (NASDAQ:XFOR [https://seekingalpha.com/symbol/XFOR]) has announced a restructuring program to align resources with its long-term strategy to complete the Phase 3 4WARD trial for chronic neutropenia. * The plan incl... Full story
Yahoo Finance • 3 months ago
X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation
Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13M John Volpone appointed Chief Operating Officer, in addition to his current role as Presiden... Full story
Yahoo Finance • 4 months ago
Sitryx appoints Adam Mostafa as Chief Financial Officer
Sitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK and Boston, MA – 8 September 2025 – Sitryx T... Full story
Yahoo Finance • 4 months ago
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on August 12, 2025, the company issued... Full story
Yahoo Finance • 4 months ago
X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement
BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today closed an upsized private placement of 11,040,776 shares of commo... Full story
Yahoo Finance • 5 months ago
X4 Pharmaceuticals secures $60 million in financing, appoints new leadership
BOSTON - X4 Pharmaceuticals (NASDAQ:XFOR) has secured approximately $60 million in a private placement financing led by Coastlands Capital, with participation from Bain Capital Life Sciences, New Enterprise Associates, and other investors,... Full story
- T
Mentioned:
Yahoo Finance • 5 months ago
X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership
$60 million PIPE financing led by Coastlands Capital, Bain Capital Life Sciences and New Enterprise Associates Newly appointed board and management team includes Dr. Adam Craig as Executive Chairman, John Volpone as President and David Ki... Full story
Yahoo Finance • 6 months ago
X4 Pharmaceuticals presents positive data from neutropenia trial
BOSTON - X4 Pharmaceuticals (NASDAQ:XFOR), a clinical-stage biotech company currently trading near its 52-week low of $2.82 (down from $31.20), presented positive results from its completed Phase 2 trial of mavorixafor in the treatment of... Full story
Yahoo Finance • 9 months ago
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line data anticipated in 2H 2026 4WARD trial protocol refined, increasing confidence in successful ou... Full story
Yahoo Finance • 10 months ago
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025
BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the fourth q... Full story
Yahoo Finance • 10 months ago
X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries
BOSTON and DUBAI, United Arab Emirates, Feb. 19, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, and taiba rare, a taiba Healthcare comp... Full story
Yahoo Finance • 11 months ago
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia
Full enrollment in ongoing global, pivotal Phase 3 clinical trial in chronic neutropenia on track for mid-2025 Right-sizing commercial efforts to optimize XOLREMDI promotion and support U.S. WHIM syndrome community Restructuring impact... Full story
Yahoo Finance • 11 months ago
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on January 31, 2025, the company issued... Full story
